Biotech Values

[biopearl]

Zip, why can't TEVA use a "forward engineered" process and do something similiar to what Sanofi does in terms of production. Momenta doesn't seem to have an issue with Sanofi's production process. If TEVA is doing something similiar that is forward engineered rather than reverse engineered, doesn't that get around the problem? Re analysis of the finished product and need for Momenta's IP to do that, Sanofi must have a way to check their own finished product or at various steps along the way, that doesn't seem to impinge on Momenta IP. Does Sanofi still have patents in place that protect against this type of forward production from a competitor? Thanks, bp